Chrissy

Results-driven pharmaceutical and specialty healthcare professional with 25+ years of success driving growth across Rare Disease, Neurology, Oncology/Hematology, Specialty Pharmaceuticals, Advanced Therapeutics and Medical Devices. Proven ability to engage academic medical centers, integrated delivery networks (IDNs), large group practices, specialty clinics, and multidisciplinary healthcare teams within complex disease states. Extensive experience developing strategic account plans, identifying appropriate patients, educating healthcare providers, navigating complex reimbursement pathways, and collaborating with cross-functional partners including Medical Science Liaisons (MSLs), Market Access, Patient Services, HUB teams, Clinical Educators, and Key Account Managers.

Recognized as a consistent top performer with multiple national awards and a proven record of successful product launches, market development, and exceeding sales objectives. Skilled in translating complex clinical information into actionable strategies that improve patient identification, access, and treatment adoption.

Senior Therapeutic Area Specialist at BRISTOL MYERS SQUIBB (2024-05 – Present)

Manage a highly complex academic oncology/hematology territory encompassing leading healthcare institutions including NYU Langone, NewYork-Presbyterian Weill Cornell, Mount Sinai, and Memorial Sloan Kettering Cancer Center. Drive clinical adoption of specialty oncology therapies across Multiple Myeloma, Lymphoma, MDS, Melanoma, and CAR-T therapeutic areas.

• Develop and execute strategic account plans focused on patient identification, referral pathways, treatment access, and growth opportunities
• Engage hematologists, oncologists, pharmacists, nurses, administrators, and multidisciplinary treatment teams
• Support CAR-T patient identification and navigation through collaboration with clinical teams and internal partners
• Successfully launched Qvantig™ for melanoma, educating healthcare providers on clinical value, patient selection, and treatment pathways
• Partner with MSLs, Key Account Managers, Market Access, and Patient Services teams to address barriers and optimize patient access
• Utilize market intelligence and account insights to identify opportunities within complex healthcare systems
• Rookie of the Year (2025)
• Melanoma Therapy Launch Accelerator Winner (2025)

Regional Business Manager at TAKEDA PHARMACEUTICALS – RARE DISEASE (2022-10 – 2024-05)

Led commercialization efforts for a subcutaneous injectable specialty therapy for Short Bowel Syndrome (SBS), an ultra-rare disease requiring complex patient identification and multidisciplinary coordination.

• Developed territory strategy to identify undiagnosed rare disease patients through collaboration with GI specialists, surgeons, nephrologists, dietitians, ostomy specialists, and multidisciplinary care teams
• Built strong relationships with healthcare providers, institutional leaders, and rare disease stakeholders to increase disease awareness and treatment adoption
• Delivered clinical education programs to physicians, residents, advanced practice providers, and healthcare teams regarding diagnostic delays, disease burden, and unmet patient needs
• Conducted account profiling activities to understand healthcare delivery models, referral patterns, and treatment barriers
• Partnered with Market Access and Patient Support teams to improve onboarding processes and reduce access challenges
• Analyzed regional market opportunities and developed strategic plans to expand treatment utilization
• Top Accelerator Award (2023)

Territory Manager at MISONIX / BIOVENTUS (2020-09 – 2022-10)

Promoted advanced biologic human tissue regeneration therapies and wound care technologies to specialty healthcare providers. Managed relationships with plastic surgeons, vascular surgeons, oncology specialists, dermatologists, podiatrists, wound centers, and hospital systems.

• Increased territory revenue 45% from 2021–2022 through strategic account development and market expansion
• Partnered with Columbia University/NYP Dermatology leadership to support treatment pathways for Epidermolysis Bullosa, a rare genetic disease
• Educated providers on reimbursement pathways, buy-and-bill processes, and patient access strategies
• Secured VAC approval at St. Barnabas Hospital
• Secured OR approval for Debridement Device and Theraskin at Westchester Medical Center and Columbia University Hospital

Territory Account Manager at BYRAM HEALTHCARE (2017-01 – 2020-10)

Managed specialty medical supply business across wound care, ostomy, and urology markets.

• Educated healthcare providers on reimbursement processes, payer requirements, and patient access solutions
• Partnered with dermatology leadership at Montefiore Medical Center to address unmet needs for patients with Hidradenitis Suppurativa (rare inflammatory disease)
• Developed territory analytics and strategic business reviews to identify growth opportunities
• Rookie of the Year (2017)
• Quota Buster (2018)
• President's Trophy (2019)

Independent Contractor at DJO GLOBAL (2015-08 – 2017-01)

• Promoted DJO's Bone growth Stimulators and braces
• Utilized established relationships to generate revenue
• Strategically cold call on orthopedic spine surgeons and podiatrists to generate new business
• Educated surgeons, nurses, residents, and patients on device utilization and clinical protocols

Territory Manager at DJO GLOBAL (2014-07 – 2015-08)

Managed specialty medical device territory focused on spine, orthopedic, podiatry, and pain management specialists.

• Educated surgeons, nurses, residents, and patients on device utilization and clinical protocols
• Developed new business through strategic prospecting and relationship development
• Quota Buster (2014)

Acute Care Territory Manager at KINETIC CONCEPTS INC. (KCI) (2013-01 – 2013-11)

Managed major Manhattan healthcare systems including NYU Langone, NewYork-Presbyterian Weill Cornell, Memorial Sloan Kettering, Lenox Hill, and Beth Israel.

• Increased territory revenue from $1.4M to $2.3M within six months
• Drove adoption of advanced wound therapies including wound VAC, Prevena, Abthera, and Veraflo
• Collaborated with procurement teams and hospital committees to secure product placement
• Successfully launched Prevena

Pain Management Specialty Representative at ENDO PHARMACEUTICALS (2005-03 – 2012-09)

Managed specialty pharmaceutical accounts across academic hospitals, specialty clinics, and office-based practices. Promoted therapies within Neurology, Rheumatology, Physiatry, and pain management specialties.

• Marketed Frova® (Migraine), Opana® (Pain Management), Fortesta® (Low Testosterone)
• Successfully launched Opana: 136% to goal
• Successfully launched Fortesta Gel: 145% to goal
• Negotiated formulary access of Opana through strategic engagement with healthcare stakeholders
• #1 Representative Nationally (1 of 400 Representatives, 2006)
• President's Club (2006)
• Regional Representative of the Year (2008, 2010)
• President's Trophy (2011)

Hospital Specialty Representative at PURDUE PHARMA (2003-10 – 2005-03)

Managed hospital-based specialty accounts across hematology, oncology, anesthesiology, and pain management.

• Promoted OxyContin®, Palladone®, and Spectracef®
• Successfully launched Spectracef and Palladone
• Secured formulary placement within healthcare institutions
• Addressed pain management needs within sickle cell populations
• Product Specialist – Palladone (2004–2005)
• Quota Buster (2004)

Professional Sales Representative at JANSSEN PHARMACEUTICALS (2000-11 – 2003-10)

Promoted specialty products to Neurology, Gastroenterology, Endocrinology, and Geriatric specialists.

• Successfully launched Reminyl achieving 144% to goal (2002)
• Developed healthcare system relationships and secured formulary access

Bachelor of Arts in Mathematics – PACE UNIVERSITY